» Articles » PMID: 20035033

Increment and Impairment of Adiponectin in Renal Failure

Overview
Journal Cardiovasc Res
Date 2009 Dec 26
PMID 20035033
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: Patients with chronic renal failure are at high risk of cardiovascular diseases. Previous studies in healthy population showed that hypoadiponectinemia was associated with high cardiovascular disease risk. However, plasma adiponectin (APN) levels are increased in renal dysfunction. Therefore, the clinical significance of plasma APN level in patients with moderate renal dysfunction is controversial. The aim of this study was to determine the change of plasma APN levels in a mouse model of renal failure and the loss of vasculo-protective function of APN in the presence of high cystatin C levels.

Methods And Results: Subtotal (5/6) nephrectomy was performed in APN-knockout (KO) mice and wild-type (WT) mice. The procedure in WT mice resulted in the significant increase of plasma APN and cystatin C levels. The clearance rate of APN was measured by injecting plasma from WT mice into KO mice. The clearance rate was significantly decreased in subtotal nephrectomized KO mice compared with sham-operated KO mice. Adiponectin protein and mRNA levels in adipose tissue were similar to subtotal nephrectomized and sham-operated mice. In cultured endothelial cells, at a high concentration corresponding to renal failure, cystatin C abolished the suppressive effects of APN on tumour necrosis factor alpha-induced expression of monocyte adhesion molecules.

Conclusion: Plasma APN increases in chronic renal failure, at least in part due to low clearance rate. High concentrations of cystatin C abolish the vasculo-protective effect of APN.

Citing Articles

Effect of leptin concentrations and leptin receptor gene polymorphisms on the outcome of renal transplantation.

Garcia-Pino G, Luna E, Mota-Zamorano S, Gonzalez L, Tormo M, Gervasini G Arch Med Sci. 2024; 20(4):1220-1227.

PMID: 39439676 PMC: 11493078. DOI: 10.5114/aoms/126343.


Adiponectin protects against myocardial ischemia-reperfusion injury: a systematic review and meta-analysis of preclinical animal studies.

Yue H, Zhang Q, Chang S, Zhao X, Wang M, Li W Lipids Health Dis. 2024; 23(1):51.

PMID: 38368320 PMC: 10874037. DOI: 10.1186/s12944-024-02028-w.


The Relationship between Serum Adiponectin, Urinary Albumin/Creatinine Ratio and Type 2 Diabetes: A Population-Based Cross-Sectional Study.

Ono S, Mizushiri S, Nishiya Y, Tamura A, Hamaura K, Ito R J Clin Med. 2022; 11(23).

PMID: 36498806 PMC: 9738010. DOI: 10.3390/jcm11237232.


Association of High Serum Adiponectin Level With Adverse Cardiovascular Outcomes and Progression of Coronary Artery Calcification in Patients With Pre-dialysis Chronic Kidney Disease.

Suh S, Oh T, Choi H, Kim C, Lee J, Oh Y Front Cardiovasc Med. 2022; 8:789488.

PMID: 35097010 PMC: 8792836. DOI: 10.3389/fcvm.2021.789488.


Adiponectin in Chronic Kidney Disease.

Przybycinski J, Dziedziejko V, Puchalowicz K, Domanski L, Pawlik A Int J Mol Sci. 2020; 21(24).

PMID: 33317050 PMC: 7764041. DOI: 10.3390/ijms21249375.